Warning! GuruFocus detected
1 Severe warning sign
with PYXS.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Pyxis Oncology Inc
NAICS : 325412
SIC : 2834
ISIN : US7473241013
Compare
Compare
Traded in other countries / regions
PYXS.USA Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2021-10-08Description
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.28 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | -0.31 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -3 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 48.3 | |||||
| 3-Year EPS without NRI Growth Rate | 50.9 | |||||
| 3-Year FCF Growth Rate | 38.3 | |||||
| 3-Year Book Growth Rate | -37.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -6.11 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.12 | |||||
| 9-Day RSI | 35.2 | |||||
| 14-Day RSI | 36.5 | |||||
| 3-1 Month Momentum % | -32.94 | |||||
| 6-1 Month Momentum % | -67.8 | |||||
| 12-1 Month Momentum % | -77.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.49 | |||||
| Quick Ratio | 7.49 | |||||
| Cash Ratio | 7.18 | |||||
| Days Sales Outstanding | 180.85 | |||||
| Days Payable | 3287 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -23 | |||||
| Shareholder Yield % | -104.26 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 97.06 | |||||
| Operating Margin % | -424.23 | |||||
| Net Margin % | -478.95 | |||||
| FCF Margin % | -358.66 | |||||
| ROE % | -51.27 | |||||
| ROA % | -40.49 | |||||
| ROIC % | -142.11 | |||||
| 3-Year ROIIC % | 11.83 | |||||
| ROC (Joel Greenblatt) % | -285.88 | |||||
| ROCE % | -39.82 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.89 | |||||
| PB Ratio | 0.45 | |||||
| Price-to-Tangible-Book | 0.46 | |||||
| EV-to-EBIT | 0.74 | |||||
| EV-to-Forward-EBIT | -0.13 | |||||
| EV-to-EBITDA | 0.77 | |||||
| EV-to-Forward-EBITDA | -0.14 | |||||
| EV-to-Revenue | -3.13 | |||||
| EV-to-Forward-Revenue | 5.48 | |||||
| EV-to-FCF | 0.87 | |||||
| Price-to-Net-Current-Asset-Value | 0.57 | |||||
| Price-to-Net-Cash | 0.6 | |||||
| Earnings Yield (Greenblatt) % | 135.14 | |||||
| FCF Yield % | -103.15 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PYXS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pyxis Oncology Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 16.146 | ||
| EPS (TTM) ($) | -1.29 | ||
| Beta | 1.19 | ||
| 3-Year Sharpe Ratio | -0.03 | ||
| 3-Year Sortino Ratio | -0.06 | ||
| Volatility % | 55.73 | ||
| 14-Day RSI | 36.5 | ||
| 14-Day ATR ($) | 0.091374 | ||
| 20-Day SMA ($) | 1.066595 | ||
| 12-1 Month Momentum % | -77.82 | ||
| 52-Week Range ($) | 0.8603 - 5.74 | ||
| Shares Outstanding (Mil) | 61.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pyxis Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pyxis Oncology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Pyxis Oncology Inc Frequently Asked Questions
What is Pyxis Oncology Inc(PYXS)'s stock price today?
The current price of PYXS is $0.91. The 52 week high of PYXS is $5.74 and 52 week low is $0.86.
When is next earnings date of Pyxis Oncology Inc(PYXS)?
The next earnings date of Pyxis Oncology Inc(PYXS) is 2025-05-14 Est..
Does Pyxis Oncology Inc(PYXS) pay dividends? If so, how much?
Pyxis Oncology Inc(PYXS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers